|
Inflammatory Bowel Diseases
|
0.130 |
GeneticVariation
|
group |
GWASDB |
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.
|
23128233 |
2012 |
|
Inflammatory Bowel Diseases
|
0.130 |
Biomarker
|
group |
BEFREE |
Specifically, a variant of the activating receptor, FcγRIIA, with low affinity for IgG, confers protection against the development of ulcerative colitis, a subset of IBD, leading to a re-evaluation of the role of IgG and FcγRs in gastrointestinal tract immunity, an organ system traditionally associated with IgA.
|
31031776 |
2019 |
|
Inflammatory Bowel Diseases
|
0.130 |
GeneticVariation
|
group |
BEFREE |
The FcgR2a*519G functional variant was associated with IBD and reduced susceptibility to UC and to CD in Caucasians.
|
20848524 |
2010 |
|
Inflammatory Bowel Diseases
|
0.130 |
Biomarker
|
group |
BEFREE |
In recent years, there has been renewed interest in the role of IgG in intestinal immunity, driven in part by a genetic association of an affinity-lowering variant of an IgG receptor, FcγRIIA, with protection from ulcerative colitis (UC), a subclass of inflammatory bowel disease (IBD).
|
31480888 |
2019 |
|
Inflammatory Bowel Diseases
|
0.130 |
GeneticVariation
|
group |
GWASCAT |
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations.
|
26192919 |
2015 |
|
Inflammatory Bowel Diseases
|
0.130 |
GeneticVariation
|
group |
GWASCAT |
Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease.
|
28067908 |
2017 |
|
Inflammatory Bowel Diseases
|
0.130 |
GeneticVariation
|
group |
GWASCAT |
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.
|
23128233 |
2012 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, the effect of FCGR polymorphisms on response confirms the importance of FCGR-mediated depletion of B cells in autoimmunity.
|
22775462 |
2012 |
|
Autoimmune Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In addition to the expected strong association with the major histocompatibility complex (MHC) region, we identified three new susceptibility loci: the immunoglobulin receptor gene FCGR2A (rs1801274, P = 1.56 x 10(-12)), a locus on chromosome 13q12 (rs17085007, P = 6.64 x 10(-8)) and the glycoprotein gene SLC26A3 (rs2108225, P = 9.50 x 10(-8)). rs1801274 is a nonsynonymous SNP of FCGR2A that is reported to have a critical effect on receptor binding affinity for IgG and to be associated with other autoimmune diseases.
|
19915573 |
2009 |
|
Autoimmune Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We also found evidence for association (P < 1 x 10(-5)) at FCGR2A, PTPN22 and STAT4, regions previously associated with SLE and other autoimmune diseases, as well as at > or =9 other loci (P < 2 x 10(-7)).
|
18204446 |
2008 |
|
Autoimmune Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The Fcgamma receptors play important roles in anti-glomerular basement membrane antibody disease (anti-GBM disease) in animal models, and FCGR gene polymorphisms have been reported to be associated with numerous human autoimmune diseases.
|
19640933 |
2010 |
|
Autoimmune Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The human FCGR2/3 locus, containing five highly homologous genes encoding the major IgG receptors, shows extensive copy number variation (CNV) associated with susceptibility to autoimmune diseases.
|
26133275 |
2015 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Nonetheless, the thrombotic complications found in some infective and autoimmune diseases may result from unbalanced FcγRIIA-mediated platelet aggregation.
|
25900780 |
2015 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
We explored the potential to prevent FcγRIIA-induced platelet activation by BTK inhibitors (BTKi's) approved (ibrutinib, acalabrutinib) or in clinical trials (zanubrutinib [BGB-3111] and tirabrutinib [ONO/GS-4059]) for B-cell malignancies, or in trials for autoimmune diseases (evobrutinib, fenebrutinib [GDC-0853]).
|
31809536 |
2019 |
|
Autoimmune Diseases
|
0.100 |
GeneticVariation
|
group |
LHGDN |
Multiplex family-based study in systemic lupus erythematosus: association between the R620W polymorphism of PTPN22 and the FcgammaRIIa (CD32A) R131 allele.
|
17092257 |
2006 |
|
Autoimmune Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The low affinity Fcγ receptor, FcγRIIA, harbors a common missense mutation, rs1801274 (G>A, Arg131His) that modifies binding affinity to human IgG2 and mouse IgG1 antibodies and is associated with increased risk of autoimmune disease.
|
29977032 |
2019 |
|
Autoimmune Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Genetic variations of the genes encoding FcγRs (FCGR genes) have been associated with susceptibility to infectious and autoimmune diseases.
|
24916518 |
2014 |
|
Autoimmune Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The FcgR2a*519GG and FcgR3a*559CC genotypes have been associated with several autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, nephritis, and possibly to type I diabetes, and celiac disease.
|
20848524 |
2010 |
|
Autoimmune Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Association of FCGR2A rs1801274 polymorphism with susceptibility to autoimmune diseases: A meta-analysis.
|
27270653 |
2016 |
|
Autoimmune Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our data suggest that the lower binding of CD32A(R) not only to IgG2 but also to IgG1 and IgG3 might be responsible for the lack of clearance of IC leading to increased susceptibility to bacterial infections and autoimmune diseases.
|
20007585 |
2009 |
|
Psychotic Disorders
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
|
Malignant Neoplasms
|
0.050 |
GeneticVariation
|
group |
BEFREE |
Thus, neutrophil ADCC capacity is directly related to the FcγRIIa polymorphism, and targeting CD47-SIRPα interactions enhances ADCC independently of FcγR and SIRPα genotype, thereby further suggesting that CD47-SIRPα interference might be a generic strategy for potentiating the efficacy of antibody therapy in cancer.
|
28952147 |
2018 |
|
Malignant Neoplasms
|
0.050 |
GeneticVariation
|
group |
BEFREE |
Significantly lower benefits were observed in patients carrying germline FCGR2A R alleles.Clin Cancer Res; 22(10); 2435-44.©2016 AACR.
|
27179112 |
2016 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
In summary, cancer cell-derived IgG interacted directly with FcγRIIa and activated platelets; targeting this interaction may be an approach to prevent and treat tumor-associated thrombosis.
|
30692520 |
2019 |
|
Malignant Neoplasms
|
0.050 |
GeneticVariation
|
group |
BEFREE |
However, particular alleles at GM 23 and FcγRIIa loci interactively contributed to the risk of this malignancy (p = 0.031), the odds ratios ranging from 0.44 in subjects homozygous for the GM 23- allele at the IgG2 locus and for the histidine allele at the FcγRIIa locus to 2.86 in subjects homozygous for the GM 23+ allele at the IgG2 locus and the histidine allele at the FcγRIIa locus.
|
23994584 |
2013 |